New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 14, 2014
07:18 EDTRXIIRXi Pharmaceuticals reports Q1 EPS (32c), one estimate (31c)
Reports Q1 revenue $29K, one estimate $80.00K.
News For RXII From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
May 21, 2015
09:29 EDTRXIIRXi Pharmaceuticals files to sell 22.5M units
Subscribe for More Information
May 13, 2015
07:10 EDTRXIIRXi Pharmaceuticals reports Q1 EPS (13c), two estimates (10c)
Subscribe for More Information
May 11, 2015
07:21 EDTRXIIRXi Pharmaceuticals presents new data on compounds targeting TYR and MMPI
RXi Pharmaceuticals presented new data on the company's proprietary self-delivering RNAi compounds developed to target Tyrosinase and Collagenase. Poster 642 presented new data from one of the Company's discovery stage programs, showing that sd‑rxRNA compounds developed to target TYR, lead to a visible reduction in pigmentation in cultured melanocytes. In vitro experiments have been carried out using a 3‑dimensional tissue culture model of human epidermis that contains melanocytes. The results of these experiments show that sd-rxRNA compounds targeting tyrosinase, in this model, are at least one hundred times more potent than kojic acid, a well-characterized skin lightening agent in reducing the melanin production in melanocytes. Poster 487 presented results on sd-rxRNA compounds targeting MMP1. In this discovery program, multiple potent sd-rxRNAs that target MMP1 have been identified and evaluated. Data from this poster show a reduction in MMP1 mRNA levels that corresponds to a similar reduction in MMP1 enzyme activity in HT-1080 cells, a cell line useful for research related to cancer of connective tissues. In addition, silencing of MMP1 expression in an in vitro scratch assay resulted in reduced migration of A549 cells, a clinically relevant non-small cell lung cancer cell line. Reduced migration in a scratch assay may indicate a reduction in the invasive nature of the cancer cell due to MMP1 reduction as a result of sd-rxRNA treatment.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use